Unresectable Stage III Non-small Cell Lung Cancer
Oncology
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| IBI363 + Chemotherapy | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Unresectable Stage III Non-small Cell Lung Cancer?
BioSniper tracks 1 drug in development for Unresectable Stage III Non-small Cell Lung Cancer across 1 company.
How many clinical trials target Unresectable Stage III Non-small Cell Lung Cancer?
There are 1 clinical trial targeting Unresectable Stage III Non-small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Unresectable Stage III Non-small Cell Lung Cancer?
The estimated prevalence of Unresectable Stage III Non-small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into Unresectable Stage III Non-small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis